Active Not RecruitingNot applicableNCT01475500

Nashville Early Diagnosis Lung Cancer Project

This screening study will address the lack of molecular strategies for the early detection of lung cancer and integrate those with epidemiological and imaging strategies. The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular analysis of biological specimens including those from bronchoscopy (bronchial brushings and biopsies) may contribute to the refinement of high-risk populations and allow an earlier clinical diagnosis. The goal of the investigators study is to provide screening for lung cancer in a high-risk population. In this prospective cohort it will be tested whether repeated measure of biomarkers of risk allows early detection of lung cancer.

Checked against the public recordLast updated Dec 12, 2023 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhaseNot applicable
U.S. locations2
SponsorVanderbilt-Ingram Cancer Center
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Vanderbilt-Ingram Cancer Center
Interventions being studied
Procedure: Sputum sample; Procedure: Pulmonary function tests; Radiation: Computerized tomography (CT) scan of the chest; Other: Buccal epithelium collection; Procedure: Nasal brushings; Procedure: Bronchoscopy; Procedure: Bronchoalveolar lavage; Procedure: Blood sample collection; Procedure: Urine sample; Procedure: Questionnaire-data collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * 55 - 80 years of age * Current smoker or former smoker. If former smoker, must have quit smoking less than 15 years ago * \>/= 30 pack year of smoking history Exclusion Criteria: * History of diagnosis/treatment of lung cancer in the past 2 years * History of head/neck or esophageal cancer in the last 1 year * Inability to provide informed consent * Participants in whom stopping anti-platelet or anti-coagulation therapy would have an adverse effect (DVT, mechanical heart valves, unstable coronary syndrome, etc.)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Veterans AdministrationNashville, Tennessee
  • Vanderbilt University, Vanderbilt-Ingram Cancer CenterNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 12, 2023. Always confirm current availability with the study team.

View original record ↗